Tarsus Historical Cash Flow
| TARS Stock | USD 48.32 0.08 0.17% |
Analysis of Tarsus Pharmaceuticals cash flow over time is an excellent tool to project Tarsus Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 86.4 M or Other Cashflows From Financing Activities of 1.5 M as it is a great indicator of Tarsus Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Tarsus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tarsus Pharmaceuticals is a good buy for the upcoming year.
Tarsus |
About Tarsus Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Tarsus balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Tarsus's non-liquid assets can be easily converted into cash.
Tarsus Pharmaceuticals Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Tarsus Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Tarsus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.At this time, Tarsus Pharmaceuticals' Sale Purchase Of Stock is comparatively stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 586K | 506K | 1.5M | 1.6M | Depreciation | 312K | 325K | 877K | 920.9K |
Tarsus Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Tarsus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tarsus Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (175K) | (456K) | (586K) | (144.1M) | 35.5M | 37.3M | |
| Change In Cash | 55.6M | 110.2M | 3.2M | (99.7M) | 153.3M | 161.0M | |
| Stock Based Compensation | 18K | 839K | 8.5M | 13.5M | 19.8M | 20.8M | |
| Free Cash Flow | (3.8M) | (21.6M) | 3.2M | (49.5M) | (123.0M) | (116.8M) | |
| Change In Working Capital | 485K | 1.5M | 1.4M | (951K) | 306K | 372.8K | |
| Begin Period Cash Flow | 2.4M | 58.0M | 168.1M | 171.3M | 71.7M | 86.4M | |
| Total Cashflows From Investing Activities | (175K) | (456K) | (586K) | (144.6M) | (130.2M) | (123.7M) | |
| Other Cashflows From Financing Activities | 4.0M | 40.1M | 21K | (365K) | 1.6M | 1.5M | |
| Depreciation | 37K | 96K | 312K | 325K | 877K | 920.9K | |
| Capital Expenditures | 175K | 456K | 586K | 506K | 1.5M | 1.6M | |
| Total Cash From Operating Activities | (3.7M) | (21.1M) | 3.7M | (49.0M) | (117.5M) | (111.6M) | |
| Change To Account Receivables | (32K) | 16K | (73K) | (3.5M) | (14.1M) | (13.4M) | |
| Change To Operating Activities | 272K | (1.8M) | (2.4M) | (1.8M) | (1.6M) | (1.7M) | |
| Issuance Of Capital Stock | 57.5M | 131.4M | 91.5M | 74.4M | 99.4M | 83.9M | |
| Net Income | (4.7M) | (26.8M) | (13.8M) | (62.1M) | (135.9M) | (129.1M) | |
| Total Cash From Financing Activities | 59.4M | 131.8M | 21K | 94.0M | 130.2M | 76.8M | |
| End Period Cash Flow | 58.0M | 168.1M | 171.3M | 71.7M | 224.9M | 127.7M | |
| Change To Netincome | 438K | 4.0M | 15.0M | 14.0M | 16.1M | 16.9M | |
| Change To Liabilities | 245K | 3.2M | 5.8M | 3.5M | 4.0M | 2.8M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.